Despite the existing range of different mechanisms and agents for the treatment of type 2 diabetes achieve two out of three Type 2 diabetics do not conform to the guidelines HbA1c target of 6.5 percent.
An important factor is the limitation of conventional therapies with side effects such as hypoglycemia, weight gain, gastrointestinal disturbances, or edema. "New treatment options are welcome," said Prof. Hellmuth Mehnert, Munich. "It would be particularly helpful to the act in the course of the disease increased beta-cell dysfunction therapeutic contrary." For the release of insulin from the beta cells in the disease process to be more and more, and hepatic glucose output increases. This has the consequence that the blood sugar rises. The usual oral antidiabetic drugs such as metformin, sulfonylureas, SUs, and alpha-glucosidase inhibitors can not affect the increase in beta cell loss. Despite therapy, insulin secretion is steadily decreasing.
One promising approach is the inhibition of the incretin-degrading enzyme dipeptidyl peptidase 4 (DPP-4). DPP-4 inhibitor sitagliptin as to prevent the degradation of endogenous incretins, so that they can exert their physiological effect of anti-diabetic longer, said Prof. Dirk Müller-Wieland, Hamburg. Incretins regulate blood sugar levels, depending on its height, that fits their effect in the current needs of the body. In clinical studies, the hypoglycaemia with sitagliptin was similar to placebo. In addition to the favorable side effect profile and the oral dosage form, treatment with sitagliptin may have another advantage: In an animal experiment that improved DPP-4 inhibitor, beta cell function.
Source:
MSD Symposium DPP-4 - a new therapeutic approach for the treatment of diabetes type 2, Fall Meeting - DDG, on 3 November 2006 in Berlin.
If this information was helpful for you, please send us a DONATION
Similar posts
